G. Thomas Budd
About
G. Thomas Budd is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, G. Thomas Budd has authored 174 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 46 papers in Cancer Research. Recurrent topics in G. Thomas Budd's work include Cancer Treatment and Pharmacology (37 papers), HER2/EGFR in Cancer Research (33 papers) and Breast Cancer Treatment Studies (31 papers). G. Thomas Budd is often cited by papers focused on Cancer Treatment and Pharmacology (37 papers), HER2/EGFR in Cancer Research (33 papers) and Breast Cancer Treatment Studies (31 papers). G. Thomas Budd collaborates with scholars based in United States, Switzerland and Canada. G. Thomas Budd's co-authors include Gerald V. Doyle, Daniel F. Hayes, Michael Craig Miller, Jeri Matera, Leon W.M.M. Terstappen, Massimo Cristofanilli, W. Jeffrey Allard, Alison Stopeck, Matthew J. Ellis and James M. Reuben and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
G. Thomas Budd
169 papers receiving 9.7k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| G. Thomas Budd United States | 37 | 6.8k | 4.1k | 2.7k | 2.3k | 1.5k | 174 | 9.9k | ||
| Stefan Sleijfer Netherlands | 61 | 7.1k 1.0× | 3.5k 0.9× | 4.7k 1.7× | 4.2k 1.8× | 1.0k 0.7× | 379 | 13.6k | ||
| Jean‐Yves Pierga France | 59 | 8.0k 1.2× | 6.3k 1.5× | 3.5k 1.3× | 2.3k 1.0× | 986 0.7× | 331 | 12.0k | ||
| Giampietro Gasparini Italy | 43 | 4.1k 0.6× | 3.4k 0.8× | 1.5k 0.5× | 5.0k 2.1× | 405 0.3× | 170 | 9.8k | ||
| Suzette Delaloge France | 56 | 8.4k 1.2× | 5.0k 1.2× | 3.8k 1.4× | 3.4k 1.5× | 746 0.5× | 399 | 13.9k | ||
| Kimberly Blackwell United States | 50 | 6.0k 0.9× | 1.9k 0.5× | 2.4k 0.9× | 2.1k 0.9× | 507 0.3× | 138 | 9.2k | ||
| Volkmar Müller Germany | 55 | 6.7k 1.0× | 5.9k 1.4× | 2.4k 0.9× | 4.4k 1.9× | 1.2k 0.8× | 319 | 11.6k | ||
| Patricia Keegan United States | 54 | 5.0k 0.7× | 1.6k 0.4× | 3.1k 1.1× | 2.1k 0.9× | 370 0.2× | 140 | 9.3k | ||
| Sabino De Placido Italy | 64 | 7.8k 1.2× | 3.7k 0.9× | 4.5k 1.7× | 4.4k 1.9× | 351 0.2× | 381 | 14.0k | ||
| Chris Twelves United Kingdom | 47 | 6.5k 1.0× | 1.7k 0.4× | 2.3k 0.8× | 2.2k 0.9× | 441 0.3× | 183 | 9.7k | ||
| Luc Dirix Belgium | 65 | 9.4k 1.4× | 4.6k 1.1× | 3.4k 1.3× | 4.4k 1.9× | 447 0.3× | 311 | 14.6k |
Countries citing papers authored by G. Thomas Budd
Since
Specialization
Citations
This map shows the geographic impact of G. Thomas Budd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Thomas Budd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Thomas Budd more than expected).
Fields of papers citing papers by G. Thomas Budd
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G. Thomas Budd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Thomas Budd. The network helps show where G. Thomas Budd may publish in the future.
Co-authorship network of co-authors of G. Thomas Budd
This figure shows the co-authorship network connecting the top 25 collaborators of G. Thomas Budd. A scholar is included among the top collaborators of G. Thomas Budd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Thomas Budd. G. Thomas Budd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Johnson, Justin M., Halle C. F. Moore, Megan Kruse, et al.. (2024). Abstract PO2-17-12: Phase I Trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC. Cancer Research. 84(9_Supplement). PO2–17.
2.
Al‐Hilli, Zahraa, Risal Djohan, G. Thomas Budd, et al.. (2024). Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast. International Journal of Radiation Oncology*Biology*Physics. 119(4). 1082–1085.
3.
Johnson, Ken B., N. Lynn Henry, Mei Wei, et al.. (2023). Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review. SHILAP Revista de lepidopterología. 4. 1139883–1139883.
4.
Zirpoli, Gary, William E. Barlow, G. Thomas Budd, et al.. (2023). Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221. Journal of the National Comprehensive Cancer Network. 21(11). 1172–1180.e3.
5.
Stabellini, Nickolas, Paul G. Pavicic, Pingfu Fu, et al.. (2023). Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer. Clinical Cancer Research. 30(1). 82–93.
6.
Cannioto, Rikki, Kristopher Attwood, Alan D. Hutson, et al.. (2023). Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Network Open. 6(5). e2311673–e2311673.
7.
Johnson, Ken B., Bihua Bie, Jennifer Hockings, et al.. (2022). A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol. Technology in Cancer Research & Treatment. 21. 2213869057–2213869057.
8.
Kruse, Megan, Mona Patel, Jeffrey M. McManus, et al.. (2021). Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. JCI Insight. 6(20).
9.
Hou, Yuan, Yadi Zhou, Muzna Hussain, et al.. (2021). Cardiac risk stratification in cancer patients: A longitudinal patient–patient network analysis. PLoS Medicine. 18(8). e1003736–e1003736.
10.
Moore, Halle C. F., Jame Abraham, Megan Kruse, et al.. (2021). Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors. Clinical Breast Cancer. 22(2). 143–148.
11.
Connolly, Roisín M., Fengmin Zhao, Kathy D. Miller, et al.. (2021). E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology. 39(28). 3171–3181.
12.
Shetty, Shashirekha, Zhen Wang, Bryce P. Portier, et al.. (2017). Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer. Cancer. 123(12). 2230–2239.
13.
Calhoun, Benjamin C., Bryce P. Portier, Zhen Wang, et al.. (2016). MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy. BMC Cancer. 16(1). 695–695.
14.
Tiwari, Shruti, Prasun Mishra, Paola Raska, et al.. (2016). Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Research and Treatment. 158(1). 189–193.
15.
Tendulkar, Rahul D., Sana Rehman, Monica Shukla, et al.. (2012). Impact of Postmastectomy Radiation on Locoregional Recurrence in Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated With Modern Systemic Therapy. International Journal of Radiation Oncology*Biology*Physics. 83(5). e577–e581.
16.
Portier, Bryce P., Zhen Wang, Erinn Downs‐Kelly, et al.. (2012). Delay to formalin fixation ‘cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Modern Pathology. 26(1). 1–9.
17.
Hicks, David G., Swati Kulkarni, Thaer Khoury, et al.. (2010). The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer. 10(1). 108–108.
18.
Budd, G. Thomas, et al.. (1996). Ifosfamide in the treatment of soft tissue sarcomas.. PubMed. 23(3 Suppl 6). 16–21.
19.
Peereboom, D., Ram Ganapathi, Olaf van Tellingen, et al.. (1996). Phase I trial of vinblastine plus phenytoin Pharmacokinetic analysis. 37. 182.
20.
Olencki, Thomas, James H. Finke, R Tubbs, et al.. (1996). Immunomodulatory Effects of Interleukin-2 and Interleukin-4 in Patients with Malignancy. Journal of Immunotherapy. 19(1). 69–80.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Stefan Sleijfer Breakdown of academic impact, for papers by Jean‐Yves Pierga Breakdown of academic impact, for papers by Giampietro Gasparini Breakdown of academic impact, for papers by Suzette Delaloge Breakdown of academic impact, for papers by Kimberly Blackwell Breakdown of academic impact, for papers by Volkmar Müller Breakdown of academic impact, for papers by Patricia Keegan Breakdown of academic impact, for papers by Sabino De Placido Breakdown of academic impact, for papers by Chris Twelves Breakdown of academic impact, for papers by Luc Dirix